Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of December 2023. The report was filed on December 21, 2023, and incorporates by reference into various Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise reporting a specific corporate event, this document does not contain financial statements.
Material Changes
The primary material change disclosed in this filing is the appointment of Phillip Hains as the new Chief Financial Officer, as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the executive appointment.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed CFO, Phillip Hains.
- Review the full text of Exhibit 99.1 for details regarding the transition of financial leadership.
- Confirm the status of the referenced Registration Statements (Forms S-8 and F-3) for potential capital raising activities.